PATHOGENETIC ASPECTS OF STATIN USE FOR PREVENTIVE AND THERAPEUTIC CORRECTION OF COGNITIVE IMPAIRMENTS OF VASCULAR GENESIS


Cite item

Full Text

Abstract

This literature review is dedicated to recent data for some pathogenetic aspects of formation and progression of cognitive impairment of vascular genesis. It was shown that preventive and therapeutic correction by statins contributes to the prevention of formation of cognitive impairment of vascular genesis and further progression to vascular dementia. Therefore, it has not only biomedical implication, but also socio-economic significance.

References

  1. Аронов Д.М. Лечение и профилактика атеросклероза. М., 2006. 309с.
  2. Аронов Д.М. Плеотропные эффекты статинов // РМЖ. 2001. Т. 9. № 13. С. 578-582.
  3. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М, 2001. 240 с.
  4. Галенко А.С., Шуленин С.Н. Способы немедикаментозной и фармакологической коррекции эндотелиальной дисфункции // ФАРМИндекс: Практик. 2006. Вып. 10. С. 2-8.
  5. Дамулин И.В. Когнитивные нарушения сосудистого генеза: клинические и терапевтические аспекты // Трудный пациент. 2006. № 6.
  6. Дамулин И.В. Постинсультная деменция: некоторые диагностические и терапевтические аспекты // Психиатрия и психофармакология. 2005. Т. 7. № 1. С. 28-32.
  7. Захаров В.В. Нарушение когнитивных функций как медико-социальная проблема // Актуальные вопросы терапии. 2006. № 5. С. 1-4.
  8. Лобзин В.Ю., Емелин А.Ю., Дремов В.В. Оценка состояния церебральной гемодинамики у больных с сосудистой деменцией с использованием ультразвукового дуплексного сканирования /Материалы VII Всероссийской научно-практической конференции "Актуальные вопросы клиники, диагности и лечения больных в многопрофильном лечебном учреждении" // Вестник Российской Военно-медицинской академии. 2005. №1 (13). С. 109.
  9. Лобзин В.Ю., Одинак М.М., Емелин А.Ю. Сосудистая деменция // Вестник Российской Военно-медицинской академии. 2005. №1 (13). С. 120-124.
  10. Оганов Р.Г., Аронов Д.М., Бубнова М.Г. Применение статинов - парадигма профилактики и лечения атеросклеротbческих заболеваний (фокус на аторвастатин) // Кардиоваскулярная терапия и профилактика. 2006. № 5(6). С. 95-107.
  11. Одинак М.М., Емелин А.Ю., Лобзин В.Ю. Нарушение когнитивных функций при цереброваскулярной патологии. СПб., 2006. 158 с.
  12. Скворцова В.И., Чазова И.Е., Стаховская Л.В. Вторичная профилактика инсульта. М., 2002. 120 с.
  13. Шкловский В.М. Концепция нейрореаблитации больных с последствиями инсульта // Журнал неврологии и психиатрии. Прил. "Инсульт". 2003. Вып. 8. С. 10-23.
  14. Яхно Н.Н. Когнитивные нарушения при инсульте. М., 2006. 214 с.
  15. Bakker S, de Leeuw F-E, de Groot JC, et al. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999;52:578-37.
  16. Pohjasvaara T, Erkinjuntii T, Ylikoski P, et al. Clinical determinants of poststroke dementia. Stroke 1998;29:75-81.
  17. Starr JM, Nicolson C, Anderson K, et al. Correlates of informant-rated cognitive decline after stroke. Cerebrovasc Dis 2000;10:214-20.
  18. Desmond DW, Moroney JT, Bagiella E, et al. Dementia as a predictor of adverse outcomes following stroke. Stroke 1998;29:69-74.
  19. Pohjasvaara T, Erkinjuntii T, Vataja R, et al. Dementia three months after stroke: baseline frequency and effect of different definitions for dementia in the Helsinski Aging Memory Study (SAM) cohort. Stroke 1997;28:785-92.
  20. Ries F, Horn R, Hillekamp J, et al. Differentiation of multi-infarct and Alzheimer dementia by intracranial hemodynamic parameters. Stroke 1993;24:228-35.
  21. Bogaty P, Dagenais GR, Poirier P, et al. Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris. Am J Cardiol 2003;92(10):1192-95.
  22. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178(2):359-63.
  23. Benfante R, Yano K, Hwang LJ, et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke 1994;25:814-20.
  24. Galea S, Langa KM, Kalbfleisch JD, et al. Pharmacotherapy 2003;23(6):726-30.
  25. Haan EH, Nys GM, Van Zandvoort MJ. Cognitive function following stroke and vascular cognitive impairment. Curr Opin Neurol 2006;19(6):559-64.
  26. Hinderliter AL, Caughey M. Assessing endothelial function as a risk factor for cardiovascular disease. Curr Atheroscler Rep 2003;5(6):506-13.
  27. Ito MK. The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type1. J Clin Pharmacol 2001;41(7):779-82.
  28. Sparks L. Statins and cognitive function. J Neurol Neurosurg Psychiatry 2009;80(1):1-2.
  29. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA Reductase inhibitors. Circulation 1998;97(2):1129-35.
  30. Lindenstrom E, Boyssen G, Nyboe J. Influence of high cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ 1994;309:11-15.
  31. Luscher TE, Noll G. The endothelium as a regulator of vascular tone and growth. The endothelium in cardiovascular disease: pathophysiology, clinical presentation and pharmacotherapy. Berlin 1995:1-24.
  32. Haan M, Nehrlich HH, Vos E. Neurology 2008;71:344-50.
  33. Miocardial Ishemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001;285:1711-18.
  34. O'Brien JT. Vascular Cognitive Impairment. Neurology 2004;63:1618-23.
  35. Terborg C, Gora F, Weiller C. et al. Reduced vasomotor reactivity in cerebral microangiopathy. A study with near-infrared spectroscopy and transcranial Doppler sonography. Stroke 2000;31:924.
  36. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelial-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89(6):2519-24.
  37. Ridker PM. Inflammatory Biomarkers. Statins and Risk of Stroke. Circulation 2002;105:2583-85.
  38. Roman GC. Facts, myths and controversies in vascular dementia. J Neurol Sci 2004;226:49-52.
  39. Roman GS. Stroke, cognitive decline and vascular dementia the silent epidemic of 21st century. Neuroepidemiology 2003;22(3):161-64.
  40. Dormuth CR, Patrick AR, Shrank WH, et al. Statin Adherence and Risk of Accidents: A Cautionary Tale. Circulation 2009;119(15):2051-57.
  41. Jack H, Zorgberg GL, Melt SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31.
  42. Van den Kommer TN, et al. Total cholesterol and oxysterols: Early markers for cognitive decline in elderly? Neurobiol Aging 2007.
  43. Provinciali L, Minciotti P, Ceravolo G, et al. Transcranial doppler sonography as a diagnostic tool in vascular dementia. EurNeurol 1990;30:98-103.
  44. Cramer C, Haan MN, Galea S, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008;71:344-50.
  45. Vos E, Nehrlich HH, Haan MN, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort. Neurology 2009;73(5):406-07.
  46. Roman GC, Sachdev P, Royall DR, et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004;226:81-87.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies